Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2019 April;67(2) > Minerva Cardioangiologica 2019 April;67(2):109-14



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Cardioangiologica 2019 April;67(2):109-14

DOI: 10.23736/S0026-4725.19.04891-6


lingua: Inglese

Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide

Gianni BELCARO 1, 2 , Mark DUGALL 1, 2, Hugh D. BRADFORD 1, 2, Maria R. CESARONE 1, 2, Beatrice FERAGALLI 1, 2, Corrado GIZZI 1, 2, Roberto COTELLESE 1, 2, Shu HU 1, 2, Patrizia RODRIGUEZ 1, 2, Morio HOSOI 1, 2

1 Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy; 2 IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland

BACKGROUND: The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema, mild antiplatelet-antithrombotic agent.
METHODS: The registry study evaluated the number of repeated episodes of RVT in 12 months. Possible managements were: standard management (SM); SM + Aspirin (100 mg/once day; if there were no tolerability problems); SM + Pycnogenol (100 mg/day); SM and ticlopidine (200 mg/day); SM + sulodexide (500 ULS/day). The number of subjects age and sex, distribution, the percent of smokers, the vision were comparable at inclusion.
RESULTS: 307 subjects completed the study, 44 in the SM group, 90 in the Pycnogenol® group, 90 in the aspirin group, 45 in the ticlopidine group and 38 in the sulodexide group. At 12 months, recurrent RVT was documented in 22.7% of controls (SM), 3.3% of Pycnogenol® subjects (P<0.05 vs. SM; 19.4% difference). There were RVTs in 15.5% subjects using Aspirin (-7.2% vs. SM). Ticlopidine also reduced (P<0.05) the incidence of RVT in comparison with SM (-9.1%). Sulodexide reduced the occurrence of new RVT (-9.5% vs. SM). Edema was better controlled with the supplement than with all other treatments (P<0.05) (edema present in only 5.5% of the Pycnogenol® subjects). Pycnogenol® had a very good tolerability and safety profile (no patient had to stop treatment).
CONCLUSIONS: Pycnogenol® is the only product able to control edema and this may reduce the incidence of recurrent RVT. This retrospective registry indicates that Aspirin, Pycnogenol®, ticlopidine an sulodexide reduce recurrent RVT without side effects. Larger studies should be planned to involve a wider range of conditions, diseases and risk factors associated with RVT and to its recurrence.

KEY WORDS: Retinal vein occlusion; Pycnogenol®; Aspirin; Ticlopidine; Glucuronyl glucosamine glycan sulfate; Blindness

inizio pagina